- A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets.
- The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale.
- The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial.
Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual property becomes just as important as clinical performance.
Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel for knee cartilage repair delivered in a single procedure of about 10 minutes, with no cell harvesting or laboratory processing. On July 20, the company strengthened its position in one of the world’s largest cartilage-repair markets.
Japan: A Substantial and Growing Market for Cartilage Repair
Aging is expanding the patient pool for the cartilage-repair opportunity across every developed market, and Asia is growing fastest. Japan is a marquee example. Published research estimates roughly 25 million people over the age of 40 in Japan have radiographic knee osteoarthritis, including about 8 million with symptomatic disease, while independent market research projects the country’s cartilage-repair market will approach $289 million by 2030. Demand is not the question. The competitive question is who can serve the market on a scale. For regenerative medicine companies, geographic expansion requires manufacturing systems capable of supporting broad adoption.
For an Off-the-Shelf Product, the Process Is the Moat
That question turns on manufacturing. Many current cartilage repair approaches rely on cell-based procedures, but their multi-step model, with tissue harvested from the patient, expanded in a laboratory over weeks, then reimplanted, is expensive and difficult to scale, which can involve significant cost and operational complexity. GelrinC is designed around the opposite model: a ready-to-use liquid formulation produced without organic solvents and intended to deliver a simpler, lower-cost alternative to cell-based procedures.
The differentiator is the manufacturing platform behind that formulation. Regentis has developed a solvent-free manufacturing method that raises yield 5-fold, simplifies production, and is built to scale for commercial supply. In a category where an off-the-shelf product only succeeds if it can be manufactured consistently and economically at volume, production capability is a critical commercial differentiator.
IP Protecting a Manufacturing Advantage in a Major Market
The July 20 announcement reinforces that strategy. The Japan Patent Office issued a Notice of Allowance for Regentis’s application covering the solvent-free protein-polymer conjugate compositions and manufacturing methods behind GelrinC’s ready-to-use formulation. Securing patent protection for that process in Japan helps protect the manufacturing approach that supports GelrinC’s scalability and commercial objectives.
“Our proprietary manufacturing technology is a key competitive advantage for GelrinC,” said Ehud Geller, CEO and Executive Chairman of Regentis. The allowance further expands a worldwide portfolio of nearly 30 granted patents spanning product composition, surgical technique, and manufacturing methods, with additional applications pending.
From Approval Toward Commercialization
Regentis is moving from clinical proof toward commercial reality. GelrinC holds CE Mark approval in the European Union, where commercialization efforts are beginning in 2026, and its pivotal U.S. trial has passed 50% enrollment, with a premarket approval preparation targeted for the end of 2027. Beyond knee cartilage repair, the Gelrin platform is also being evaluated for additional applications, including smaller joints and earlier-stage osteoarthritis indications.
The clinical case for GelrinC has been building for years through published imaging and outcome data. The Japanese patent allowance highlights that transforming clinical progress into a global commercial product depends not only on therapeutic performance, but also on manufacturing capability and intellectual property protection. While regulatory approval and clinical outcomes remain the ultimate determinants of success, Regentis is building the operational foundation needed to compete in the expanding cartilage-repair market.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT
This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai
RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN